Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John G. Connolly is active.

Publication


Featured researches published by John G. Connolly.


Journal of Steroid Biochemistry | 1975

In vitro assay of androgen binding by human prostate

B. G. Mobbs; I.E. Johnson; John G. Connolly

Abstract The in vitro binding of 5α-dihydrotestosterone by a “cytosol” fraction of human pathological tissue was investigated, and compared with binding by the rat prostate, an androgen-responsive mouse mammary tumour, and some androgen-unresponsive control tissues. Androgen-binding levels in the human control tissues were higher than those in the rat and mouse, and were not lower than androgen-binding levels in many prostatic specimens from untreated patients. Estrogen therapy and/or orchiectomy appeared to result in higher binding levels. The steroid specificity of binding in the human prostatic tissue appeared closer to that of sex hormone binding globulin than to that of the androgen receptor in the rat prostate. It was concluded that the assay used was not sufficiently specific to distinguish androgen binding by sex hormone binding globulin from that by an intracellular prostatic androgen receptor.


Journal of Steroid Biochemistry | 1977

Evaluation of the use of cyproterone acetate competition to distinguish between high-affinity binding of [3H]-dihydrotestosterone to human prostate cytosol receptors and to sex hormone-binding globulin

B. G. Mobbs; I.E. Johnson; John G. Connolly; A.F. Clark

From preliminary experiments, it was concluded that cyproterone acetate (CA) was the most satisfactory of several anti-androgens investigated in distinguishing between high-affinity binding of [3H]-5α-dihydrotestosterone to rat ventral prostate cytosol and to human serum, using a simple incubation technique followed by removal of free steroid by Dextran-coated charcoal. Rat prostate cytosol (androgen receptor) binding of [3H]-DHT was almost eliminated by concentrations of CA which affected human serum binding to a relatively slight, though unfortunately variable, extent. n nThe total, high-affinity, and CA-inhibitable binding of [3H]-DHT by prostatic cytosol of a number of patients with benign prostatic hypertrophy and prostatic carcinoma was investigated. In the untreated patients and in some patients treated by orchidectomy and/or estrogens, the total and CA-inhibitable high affinity binding of [3H]-DHT were correlated with the endocrine status of the patient as determined by the serum testosterone level and the high affinity [3H]-DHT binding capacity of the serum (equivalent to sex-hormone binding globulin (SHBG)). n nIt was concluded that the use of cyproterone acetate to distinguish between [3H]-DHT binding to the androgen receptor and serum components in human prostate cytosol permits a semi-quantitative evaluation of the amounts of these two components.


Mutation Research\/genetic Toxicology | 1995

Application of urinary mutagen testing to detect workplace hazardous exposure and bladder cancer

Bernard C. K. Choi; John G. Connolly; Rosa H. Zhou

The objectives of this biochemical epidemiologic case-control study were to evaluate urinary mutagen testing for occupational exposure assessment, and for possible screening for bladder cancer in the workplace. Thirty-seven patients (19 bladder cancer cases and 18 controls) completed a questionnaire. Two urine samples, i.e. a work sample taken while at work, and a home sample, were requested from each patient. Twenty-six patients (17 cases and 9 controls) gave a total of 47 24-h urine samples for mutagenicity testing by the Ames test. A positive Ames test was found to be associated significantly with current occupation with hazardous exposure (odds ratio = 3.7, 95%CI 1.1-12.9), and non-significantly with bladder cancer (odds ratio = 1.8, 95%CI 0.5-7.1). Our results show that the urinary Ames test has the potential of being used as a surveillance for current workplace hazardous exposure (sensitivity = 52%, specificity = 77%, positive predictive value = 72%, negative predictive value = 59%, positive likelihood ratio = 2.3), but not as a screening test for bladder cancer cases (sensitivity = 42%, specificity = 71%, positive predictive value = 3%, negative predictive value = 98%, positive likelihood ratio = 1.5).


Urology | 1974

Hormonal responsiveness of prostatic carcinoma: in vitro technique for prediction.

Betty G. Mobbs; Ivy E. Johnson; John G. Connolly

Abstract An attempt to establish an in vitro technique to assist in selecting the most appropriate therapy for patients with prostatic carcinoma is presented.


Urology | 1973

Synkavit Radios en sitizing agent in prostatic carcinoma

Gwyneth M. Halsall; John G. Connolly; Betty G. Mobbs; Carol Promislow

Abstract Six male cynomolgus monkeys were intravenously injected with 10 microcuries per pound of tritiated synkavit and 0.67 mg. per pound of carrier synkavit. Two animals were sacrificed at fifteen minutes, two at thirty minutes, and two at one hour after injection. Samples of caudal prostate, bladder, testis, spleen, liver, lung, upper and lower intestines, skin, muscle, fat, urine, and serum were removed. At fifteen minutes the concentration of menadione in the prostate gland was 2.26 × 10 −6 M, which is more than that found in any other tissue. This level is sufficient for radiosensitization.


Proceedings of the Fourth International Congress on Hormonal Steroids#R##N#Mexico City, September 1974 | 1976

IN VITRO ASSAY OF ANDROGEN BINDING BY HUMAN PROSTATE

Betty G. Mobbs; Ivy E. Johnson; John G. Connolly

The in vitro binding of 5α-dihydrotestosterone by a “cytosol” fraction of human pathological tissue was investigated, and compared with binding by the rat prostate, an androgen-responsive mouse mammary tumour, and some androgen-unresponsive control tissues. Androgen-binding levels in the human control tissues were higher than those in the rat and mouse, and were not lower than androgen-binding levels in many prostatic specimens from untreated patients. Estrogen therapy and/or orchiectomy appeared to result in higher binding levels. The steroid specificity of binding in the human prostatic tissue appeared closer to that of sex hormone binding globulin than to that of the androgen receptor in the rat prostate. It was concluded that the assay used was not sufficiently specific to distinguish androgen binding by sex hormone binding globulin from that by an intracellular prostatic androgen receptor.


Cancer Research | 1992

Antibody Drug Carrier for Immunotherapy of Superficial Bladder Cancer: Ultrastructural Studies

Etienne de Harven; Yves Fradet; John G. Connolly; Wedad Hanna; Shaomu He; Yanchun Wang; Bernard C. K. Choi; Roy McGroarty; George Bootsma; Aina Tilups; Hilary Christensen


The Journal of Urology | 1983

Re: Immunotherapy of Superficial Bladder Cancer, by Amos Shapiro, Dov Kadmon, William J. Catalona and Timothy L. Ratliff, J. Urol., 128: 891–894, 1982

John G. Connolly


Urology | 1975

Use of mycophenolic acid in superficial bladder cancer

John G. Connolly; G.M. Halsall


The Journal of Urology | 1972

Some Arguments against the use of Mucosal Stripping in the Treatment of Recurrent, Superficial Cancer of the Bladder

John G. Connolly

Collaboration


Dive into the John G. Connolly's collaboration.

Top Co-Authors

Avatar

Betty G. Mobbs

Women's College Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G.M. Halsall

Women's College Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ivy E. Johnson

Women's College Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge